Citicoline vs Alpha-GPC: Which Has the Better Evidence

Both are choline donors, and their evidence bases are not comparable. Alpha-GPC has the larger measured effect — a 2023 meta-analysis of 8 studies and 861 participants found an MMSE mean difference of 3.50 for monotherapy versus placebo — but almost every one of those trials was run in clinical dementia populations at 1,200 mg/day, and a Korean national cohort of over 12 million adults associated alpha-GPC use with a 43% higher 10-year stroke risk. Citicoline’s evidence is more modest and better tolerated, concentrated in age-related and vascular cognitive impairment at 250–1,000 mg/day. For a healthy adult, neither has convincing data, and citicoline is the one with the cleaner safety record.

Contains alpha-GPC — at a fraction of the trial dose

Neuro-Thrive

Neuro-Thrive is one of the few formulas in this category that publishes a complete dose panel: bacopa monnieri 300 mg at 50% bacosides, alpha-GPC 150 mg, GABA 100 mg, PQQ 10 mg, vitamin D3 20 mcg, niacin 8 mg, vitamin B6 5 mg. Say plainly what that alpha-GPC figure means: 150 mg is not the trial dose — nearly all the clinical evidence used 1,200 mg/day, so this is one-eighth of it and the dementia trial results do not transfer. Its PQQ is also 10 mg where the cognitive trial used 20 mg/day. And because it contains alpha-GPC at all, the Korean stroke association applies: anyone with cerebrovascular history, uncontrolled hypertension or on anticoagulants should raise it with a clinician first.

We earn a commission if you buy through this link. It costs you nothing extra and it does not change what we write.

Full Neuro-Thrive review: doses, price, guarantee →

Check the current price →

Written by the Fog & Clarity editorial team · Published 2 September 2026 · Last updated 2 September 2026

At a glance

	Citicoline	Alpha-GPC
Evidence tier	Moderate	Moderate for efficacy; carries a safety signal
Best-evidenced population	Age-related and vascular cognitive impairment	Mild-to-moderate Alzheimer’s and vascular dementia
Typical trial dose	250–1,000 mg/day	1,200 mg/day (400 mg three times daily)
Healthy-adult data	Thin, often industry-funded	Essentially an extrapolation
Main safety concern	None serious reported, incl. use up to 3 years	43% higher 10-year stroke risk in a Korean cohort

What each one actually is

Citicoline is cytidine 5′-diphosphocholine, sold as the branded ingredient Cognizin and available as the prescription drug Somazina or Ceraxon in parts of Europe and Latin America. It donates both choline and cytidine, the latter feeding into phospholipid synthesis.

Alpha-GPC is L-alpha-glycerylphosphorylcholine, also called choline alfoscerate, and is a prescription product in Italy and Korea under names including Gliatilin. It is marketed as the most bioavailable choline source and appears in both cognitive and sports formulas.

Both are, at bottom, ways of raising choline availability. Neither is a novel mechanism, and the difference between them is not chemistry — it is who was studied, at what dose, and what turned up in the safety data.

Evidence quality compared

Alpha-GPC has the more impressive numbers. A 2023 systematic review and meta-analysis by Sagaro and colleagues in the Journal of Alzheimer’s Disease pooled 8 studies and 861 participants from Russia, Italy and Mexico. Alpha-GPC monotherapy versus placebo produced an MMSE mean difference of 3.50 (95% CI 0.36–6.63); combined with donepezil, MMSE MD 1.72 and ADAS-Cog MD −5.76.⁴ A three-point MMSE difference is clinically non-trivial.

Now the qualifications, which are the honest heart of this comparison. Those effects were measured in dementia patients, mostly alongside donepezil, in trials heavily concentrated in Italian research groups (the ASCOMALVA programme), at 1,200 mg/day. There is no convincing healthy-adult cognitive data for alpha-GPC at all. Everything sold to a healthy 40-year-old on the strength of these numbers is an extrapolation across population, dose and co-medication simultaneously.⁶

Citicoline’s claim is narrower and, in a sense, more honest by construction. What the evidence supports is modest benefit in age-related and vascular cognitive impairment, plus small acute effects on attention and processing speed in lower-performing individuals.¹² One trial found that participants with high baseline performance showed slight declines — a detail worth sitting with if you are a high performer buying it to go higher.

Citicoline also has a substantial negative result the marketing never mentions. In acute ischemic stroke, where it was studied most rigorously and in large trials, it has not shown benefit relative to current standard of care.¹ That is where the strongest test happened, and it failed.

One further note on sourcing. EFSA issued an Article 13(5) opinion on citicoline and memory in 2024. We have not been able to read its conclusion directly, and Article 13(5) health claims are usually not substantiated, so we do not cite it as supportive or as negative.³ Flagging what we could not verify is part of how we rate evidence.

The alpha-GPC safety signal

⚠️ The single most important datum on alpha-GPC

A population-based retrospective cohort using South Korea’s National Health Insurance Service database — over 12 million adults aged 50+, comparing 108,877 alpha-GPC users against 11.9 million non-users over 10 years of follow-up — found adjusted hazard ratios of 1.43 for total stroke, 1.34 ischemic and 1.37 hemorrhagic, with a dose-response relationship.⁵ Anyone with cerebrovascular disease, prior stroke or TIA, uncontrolled hypertension, or taking anticoagulants should not take alpha-GPC without a clinician’s involvement.

Stated once and stated fairly: this is observational, and confounding by indication is a real concern. People prescribed alpha-GPC in Korea are, by definition, people presenting with cognitive complaints — a group already at higher vascular risk. An association in a cohort study is not a demonstrated risk, and this one has not been tested in a randomized trial.

What keeps it from being dismissible is the scale and the dose-response gradient, which is the pattern you would expect if the relationship were causal. The literature is also genuinely conflicted: a separate Korean analysis has suggested delayed dementia conversion in alpha-GPC users, and both findings belong in the same sentence rather than being quoted in isolation.⁷ The full account is in the alpha-GPC stroke signal.

Citicoline, by comparison, is among the best-tolerated agents in this whole reference: no serious safety issues reported, including in use up to three years, with mild gastrointestinal upset, headache and insomnia the usual complaints.¹ Its one flagged interaction is with levodopa and other Parkinson’s medications, and it is poorly characterized.

Where each one has the better case

Alpha-GPC has the better case in one narrow situation: a person with diagnosed mild-to-moderate Alzheimer’s or vascular dementia, under clinical supervision, already taking donepezil, where 1,200 mg/day as an add-on has the meta-analytic support. That is a prescribing decision, not a shopping decision, and it belongs to the treating clinician.

Citicoline has the better case everywhere else, mostly by default. Older adults with age-associated memory impairment or vascular cognitive impairment have the most relevant data. Adolescents and adults with low baseline attention performance have some acute signal. And the safety profile means the downside of being wrong is small.

Neither has a case for a healthy, high-performing adult who wants sharper focus. Citicoline’s own data hint at slight declines in high-baseline performers; alpha-GPC has no healthy-adult evidence and a safety association attached. “Neither, for most people” is the accurate answer to this comparison, and it is the one we would give a friend.

Cost per effective dose

Prices move constantly, so treat any figure as approximate and check at the time you buy. What does not move is the dose arithmetic, and it runs against alpha-GPC.

Alpha-GPC at the trial dose means 1,200 mg/day, typically 400 mg three times daily. Most consumer capsules contain 150–600 mg, so reaching the studied dose means several capsules a day — and multiplies the cost accordingly.
Citicoline at the studied dose means 250–500 mg/day for healthy-adult and Cognizin trials, 500–1,000 mg/day for clinical work. One capsule usually covers it.
More is not better with citicoline. Independent analysis suggests lower doses around 250 mg may be more effective than higher ones in healthy people, and EFSA guidance cited by the same source sets 500 mg/day as a supplement maximum.¹

The practical consequence is that a formula containing 150 mg of alpha-GPC is not a cheaper version of the intervention. It is a different, untested amount. Per-ingredient dosing is exactly what proprietary blends are designed to obscure, and it is worth checking before comparing prices at all.

Can you take both

Nobody has tested the combination for cognition, so there is no evidence either way — this is reasoning from pharmacology, not from data. Both raise choline availability by different routes, so stacking them is mostly a way of paying twice for the same mechanism while carrying alpha-GPC’s safety question.

Both are also additive with cholinesterase inhibitors — donepezil, rivastigmine, galantamine — and neither should be stacked on prescribed cholinergic treatment without a clinician. Both should stop at least two weeks before surgery along with other supplements; see supplements to stop before surgery. There is also a mechanistic hypothesis that dietary choline raises TMAO, a proposed mediator of atherosclerosis, which is one plausible route by which the alpha-GPC association could be real.

What would change our mind

Two studies. For alpha-GPC, a randomized trial with adjudicated cardiovascular endpoints in non-demented adults — the only design that can settle whether the Korean stroke association is causal or is confounding by indication. For citicoline, an adequately powered trial of 250–500 mg/day in healthy adults with pre-registered attention and memory endpoints, since the current healthy-adult literature is thin and often industry-funded. Either result would rewrite this comparison.

Frequently asked questions

Is alpha-GPC stronger than citicoline?

It shows a larger effect on paper — an MMSE mean difference of 3.50 versus placebo — but that was measured in dementia patients at 1,200 mg/day, mostly as an add-on to donepezil. “Stronger” in a population you don’t belong to, at a dose your capsule doesn’t contain, is not a useful comparison.

Is 150 mg of alpha-GPC enough to do anything?

Nobody knows, because it has not been tested for cognition at that dose. The clinical evidence sits at 1,200 mg/day; sports and acute-cognition studies used 300–600 mg. At 150 mg you are below all of them, so no trial result applies.

Does citicoline work for healthy people?

It is not established in healthy high-performing adults, and one trial found slight declines in participants with high baseline performance. The clearest signal is in older adults with age-associated memory impairment and in people with low baseline attention.

Who should avoid alpha-GPC entirely?

Pending better data, anyone with cerebrovascular disease, a prior stroke or TIA, uncontrolled hypertension, or who takes anticoagulants — and anyone already on a prescribed cholinesterase inhibitor, without their clinician’s agreement.

Sources

These statements have not been evaluated by the Food and Drug Administration. Nothing here is intended to diagnose, treat, cure or prevent any disease.

This article is information, not medical advice. Talk to a doctor or pharmacist about your own situation, especially if you take prescription medication.